title: Pharmacogenomics and its potential impact on drug and formulation development.
abstract: Recent advances in genomic research have provided the basis for new insights into the importance of genetic and genomic markers during the different stages of drug development. A new field of research, pharmacogenomics, which studies the relationship between drug effects and the genome, has emerged. Structural pharmacogenomics maps the complete DNA sequences of whole genomes (genotypes) including individual variations, and functional pharmacogenomics assesses the expression levels of thousands of genes in one single experiment. Together, these two areas of pharmacogenomics have generated massive databases, which have become a challenge for the research field of informatics and have fostered a new branch of research, bioinformatics. If skillfully used, the databases generated by pharmacogenomics together with data mining on the Web promise to improve the drug development process in a variety of areas: identification of drug targets, evaluation of toxicity, classification of diseases, evaluation of formulations, assessment of drug response and treatment, post-marketing applications, and development of personalized medicines.
authors.affiliation: Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CN 06269, USA. karin.regnstrom@uconn.edu
authors.forename: Karin
authors.initials: K
authors.lastname: Regnstrom
authors.forename: Diane J
authors.initials: DJ
authors.lastname: Burgess
mesh_terms: D000818:Animals; D002626:Chemistry, Pharmaceutical / Q000331:legislation & jurisprudence / Q000379:methods*; D019295:Computational Biology / Q000331:legislation & jurisprudence / Q000379:methods*; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004345:Drug Industry / Q000379:methods; D006801:Humans; D066298:In Vitro Techniques; D020411:Oligonucleotide Array Sequence Analysis; D010597:Pharmacogenetics / Q000331:legislation & jurisprudence / Q000379:methods*; D011110:Polymorphism, Genetic; D011358:Product Surveillance, Postmarketing; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014481:United States; D014486:United States Food and Drug Administration